Alliance predicts positive full-year results
This article was originally published in Scrip
Alliance Pharma had a turnover of £21.8 million last year and expects to exceed market expectations for its full-year results, which will be released in March. Turnover in the second half of last year was £11.9 million, an increase of 20% compared with the first half of the year. Alliance now expects pre-tax trading profits of at least £2.3 million. Michael Gatenby, Alliance's chairman, said the company's sales were mainly prescription driven and were therefore largely unaffected by economic conditions. Existing shareholder Nigel Wray has purchased a further one million ordinary shares at 1p each. Mr Wray, who also owns the rugby club Saracens and has a £78 million stake in Domino's Pizza UK & Ireland, now holds around 12.2 million Alliance shares, equivalent to 7.5% of the company's issued share capital.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.